CollaGenex Pharmaceuticals Announces Fourth Quarter and Year End 2001 Earnings Conference Call.Business Editors NEWTOWN, Pa.--(BUSINESS WIRE)--Feb. 4, 2002 CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI CGPI Corporate Goods Price Index (Japan) CGPI Capital Goods Price Index (New Zealand) ) today announced that it will hold a conference call on Tuesday, February 12, 2001, at 11:00 a.m. (Eastern Time) to discuss the company's fourth quarter and year end 2001 operating and financial results. Brian M. Gallagher, Ph.D., chairman, president and chief executive officer, and Nancy C. Broadbent, chief financial officer, of CollaGenex will host the conference call. Investors and other interested parties can access the conference call by dialing 800/450-0788 or via a live Internet broadcast on the company's website at www.collagenex.com or CCBN's website at www.streetevents.com. For those who cannot listen to the live broadcast, a replay will be available shortly after the call on the company's web site at www.collagenex.com or www.streeevents.com for 90 days or by dialing 800/475-6701 and entering access code 625157 until 11:59 p.m. on February 26, 2002. About the Company CollaGenex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on providing innovative medical therapies to the dental and dermatology dermatology (dûrmətŏl`əjē), branch of medicine concerned with diagnosis and treatment of diseases and disorders of the skin. markets. The company's lead product, Periostat(R), was approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. in September 1998 and is the first and only pharmaceutical to treat periodontal disease Periodontal Disease Definition Periodontal diseases are a group of diseases that affect the tissues that support and anchor the teeth. Left untreated, periodontal disease results in the destruction of the gums, alveolar bone (the part of the jaws where by inhibiting the enzymes that destroy periodontal periodontal /peri·odon·tal/ (per?e-o-don´t'l) 1. pertaining to the periodontal ligament or periodontium. 2. near or around a tooth. per·i·o·don·tal adj. 1. support tissues. Periostat is marketed to the dental community by CollaGenex through a professional pharmaceutical sales force composed of approximately 120 sales representatives and managers. Currently, the company's dental sales force is also marketing Vioxx(R), a Merck & Co. drug that the company co-promotes for the treatment of acute dental pain, and Atridox(R), Atrisorb(R) and Atrisorb-D(R), Atrix Laboratories Inc.'s products for the treatment of adult periodontitis periodontitis Inflammation of soft tissues around the teeth (see tooth). Poor dental hygiene leads to deposition of bacterial plaque on the teeth below the gum line, irritating and eroding nearby tissues. . In a clinical trial completed during 2001, Periostat also demonstrated efficacy in the treatment of acne, and the Company intends to initiate a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the in acne in 2002 . To receive additional information on the Company, please visit our Web site at www.collagenex.com, which is not a part of this press release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion